Not connected to GLP3Planner: GLP3Planner has no connection to “GLP3-B” capsules or any shop selling them through social media ads. We don't sell medication, supplements or peptides and never take orders. For an order or refund, contact the seller or your bank or card provider.

Knowledge Base

Resources & Guides

Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.

Showing articles tagged: #compounded retatrutide Clear filter

Educational Content

View all →
Showing 4 of 4 articles
No articles found matching your search. Try a different term or view all articles.

Compounded Retatrutide: Legal Status, Risks & Alternatives

Unlike semaglutide and tirzepatide, compounded retatrutide is explicitly prohibited under federal law — there is no approved version, so the shortage exemption never applied. This guide explains the legal reality, what's actually in research-peptide vials, and what your real options are.

Where to Get Retatrutide in 2026: Availability by Source

Retatrutide is not commercially available. Phase 3 results have been reported and Lilly plans an FDA filing in early 2027, with a decision possible in late 2027 or 2028 (our estimate, not Lilly's). In the US, lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). Compounding pharmacies cannot lawfully supply it. Here is everything you need to know about retatrutide availability worldwide.

Retatrutide Cost: $150 to $1,500/mo by Source (2026 Prices)

Retatrutide has no official price. It's still in Phase 3 clinical trials. This guide covers what people actually pay today for research peptides, why compounded retatrutide is not a lawful option, what it will likely cost at commercial launch, and how it compares to tirzepatide and semaglutide.

How to Get Retatrutide: Clinical Trials and Expanded Access Are the Only Lawful Routes

Retatrutide isn't FDA-approved yet. Lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). This guide covers how to join a trial, who qualifies for expanded access, why compounding pharmacies cannot lawfully supply retatrutide, and what research peptide vendors actually sell, plus what you need to know about safety, legality, and costs.